Local Application of Corticosteroids Combined with Surgery for the Treatment of Chronic Subdural Hematoma

Kronik Subdural Hematom Tedavisinde Cerrahi ile Kombine Olarak Lokal Kortikosteroid Uygulaması

Xiao-Ping XU, Cong LIU, Jian LIU, Yuan-Guang PANG, Xu-Dong LUO, Jun FU, Liang ZHOU, Ying-Zhong FAN
The First People's Hospital of Neijiang, Department of Neurosurgery, Neijiang, Sichuan, China

Corresponding Author: Cong LIU / E-mail: njyyliucong@163.com

ABSTRACT

AIM: Combination treatment consisting of surgery and pre- or post-operative corticosteroids for chronic subdural hematoma (CSH) tend to have better outcomes than surgery only. However, there are many complications after long-term use of corticosteroids. In this study, we evaluated the clinical outcomes of local application of corticosteroids combined with surgery for CSH.

MATERIAL and METHODS: We retrospectively analysed the data of the patients undergoing surgery and local application of Methylprednisolone Sodium Succinate for Injection (MPSS) into the hematoma cavity. Neurological status was assessed by Markwalder’s Grading Scale (MGS). Recurrence was defined as deteriorating neurological status with radiological evidence of reaccumulation.

RESULTS: A total of 26 patients were enrolled in this study. During the follow-up period, all patients made excellent neurological recovery. 24 (92.3%) patients’ MGS was grade 0 at 12 months after the surgery. There was no mortality or recurrence. 5 patients (19.2%) suffered postoperative complications, of which 2 developed some subdural air collection, 2 had a partial seizure attack and 1 developed an acute epidural hemorrhage.

CONCLUSION: The results suggest that local application of MPSS combined with surgery is a safe and effective method in the management of CSH. It may reduce hematoma recurrence.

KEYWORDS: Chronic subdural hematoma, Surgery, Corticosteroids, Local application

ÖZ


BULGULAR: Çalışmaya toplam 26 hasta dahil edildi. Takip dönemde tüm hastalar nörolojik açıdan iyileşti. Yılda %92,3 hastada cerrahiden 12 ay sonra MGS 0 olarak bulundu. Mortalite veya nüks yoktu. Beş hastada (19,2%) postoperatif komplikasyonlar görüldü ve bunların 2’sinde bir miktar subdural hava toplanması, 2’sinde kısmi havale atığı ve 1’inde akut epidural kanama gelişti.

SONUC: Sonuçlarımız, cerrahiyle kombine olarak yerel MPSS uygulamasının kronik subdural hematom yönetiminde güvenli ve etkin bir yöntem olduğunu işaret etmektedir. Hematom nüksünü de azaltabilir.

ANAHTAR SÖZÇÜKLER: Kronik subdural hematom, Cerrahi, Kortikosteroidler, Lokal uygulama

INTRODUCTION

Chronic subdural hematoma (CSH) has been treated with various procedures. In most cases surgical treatment is the first choice and its clinical outcome is good, but have experienced a considerable number of cases in which surgical complications and recurrence rates are high. Many researchers also reported the efficacy of general use of dexamethasone (oral or intravenous) in the treatment of CSH, and obtained favourable results (4, 5, 24). Combination treatment consisting of surgery and pre-operative or post-operative corticosteroids tends to have better outcomes (2, 3, 5, 6, 24), but there can be complications such as infections, gastrointestinal bleeding, and hyperglycemia after general administration of long-term corticosteroids. Endo et al. reported successful treatment of a case of infantile subdural fluid collection by injection of 8 mg methylprednisolone acetate (MPA) into the subdural cavity (7). However, to our knowledge, there is no report of local
use of corticosteroids in the management of CSH. Here we report the clinical results of 26 patients treated by local use of corticosteroids into the hematoma cavity combined with surgery.

**MATERIAL and METHODS**

We retrospectively analysed the data of 26 patients with CSH who were admitted to the Department of Neurosurgery, First People’s Hospital of Neijiang, China, where they underwent surgery and received a local application of Methylprednisolone Sodium Succinate for Injection (MPSS) into the hematoma cavity between January 2003 and March 2007. This study was conducted in accordance with the declaration of Helsinki and under approval from the Ethics Committee of the First People’s Hospital of Neijiang, China. Written informed consent was obtained from all participants. All cases of CSH were diagnosed by computed tomographic scanning (CT) and/or magnetic resonance imaging (MRI).

**Surgical Procedure**

The patients were kept in a lateral position, except 3 patients with bilateral CSH needing repositioning during operation. We treated bilateral hematomas as one case, and both sides received the same treatment. Under local anesthesia, while general anesthesia was performed when anesthetics judged it to be too risky for surgery. A single burr hole was drilled over the maximum thickness of the hematoma, and the hematoma cavity was intensively irrigated with physiological saline solution using a small catheter mounted on a syringe. The catheter was manipulated into the corners of the cavity to wash out the clots and insure free communication of all parts of the cavity. When the irrigation fluid was clear, the hematoma cavity was filled with physiological saline solution and a post-operative closed drainage system with a ventricular catheter mounted on a T-tubes was inserted in the frontal subdural space. 48-72 hours later, when drainage had ceased, 10 mg of Methylprednisolone Sodium Succinate for Injection (MPSS) was dissolved in 5 ml saline and administrated into the hematoma cavity through the T-tubes. Then the drainage system was removed.

**Follow-up Study**

CT scan and/or MRI was performed on admission, at the time when the drainage system was removed, and at 12 months after the operation if patients’ symptoms did not recur. Neurological status was assessed by Markwalder’s Grading Scale (MGS), which is the most commonly used neurological grading system for CSH, on admission, 1 day after the operation, at discharge and 12 months after the operation (15). Recurrence was defined as deteriorating neurological status with radiological evidence of reaccumulation.

**RESULTS**

A total of 26 consecutive patients with a diagnosis of CSH were included. The mean duration of hospitalization was 6.7 days. Mean age was 65.8 years, ranging from 10 to 85 years and there were 23 men and 3 women. 84.6% of the patients were treated under local anesthesia, and 4 patients under general anesthesia. A single burr hole was drilled in 23 patients (left: right=17: 6), and bilateral drilling was performed in 3 patients. 76.9% of the patients revealed a previous history of mild or moderate head trauma several weeks/months before admission. Other risk factors included hypertension (19.2%), anticoagulant medication intake (30.8%), cardiomyopathy (11.5%), and type-2 diabetes (3.8%).

Headache and instability were the most common symptoms (69.2%), followed by mental confusion, drowsiness and impaired cognition. The indication for surgery was based mainly on progressive neurological deficits and midline shift of some degree on CT findings. On admission, 23 patients harboured a unilateral CSH and 3 were bilateral. All the unilateral CSH patients were found to have midline shift of some degree.

There was no mortality and we observed good recovery of neurological status at discharge for most patients (Table I). Post-operative complications were also recorded with 2 patients developing some subdural air collection, 2 with a partial seizure attack and 1 patient suffering from an acute epidural hemorrhage near the drilling site with no need for a second surgical intervention. 12 months after the operation, 92.3% of the patients’ Markwalder score was grade 0. During the 12-month follow-up, no patient had symptoms or radiological evidence of recurrence.

**DISCUSSION**

Up to now, there have been no studies to determine which surgical approach is most appropriate for the treatment of CSH. As has been presented, we combined surgery and local application of MPSS into the hematoma cavity to treat CSH, and excellent neurological recovery was found. At 12 months after the operation, 24 patients’ Markwalder score was grade 0. Surprisingly, no recurrence and negative side effects of local application of MPSS were observed, which suggests that local application of MPSS combined with surgery for the treatment of CSH is effective and safe.

To our knowledge, this is the first time of local use MPSS in the management of CSH. Shunro Endo et al. (7) reported successful treatment of a case of infantile subdural fluid collection by administration of 8 mg methylprednisolone acetate (MPA) into the subdural cavity when continuous subdural drainage and subdural peritoneal shunt failed. A questionnaire survey showed that 42% responded that they never prescribed corticosteroids and 55% stated that they prescribed them only to those managed conservatively (21). Previous studies showed that general application of corticosteroids (oral or intravenous or intramuscular) obtained favourable results (5, 24). Delgado-López et al. large retrospective series (101 cases) suggested that dexamethasone was a feasible and safe alternative in the management of CSH (5), but it could only be applied to a small number of selective patients. Combination treatment consisting of surgery and corticosteroids either given before or after surgery seems to have better results
Corticosteroids Combined with Surgery for CSH (2, 3, 5, 24), but negative side effects of general application of the corticosteroids such as hyperglycemia, nosocomial infections, gastrointestinal bleeding etc. were observed when used for longer periods, the frequency and severity of adverse effects increases dramatically. Local use of corticosteroids can minimize the side effects, and excellent recovery and no recurrence were observed in our report.

Contemporary options for treating CSH range from simple twist drill craniostomy without drainage to large craniotomies with marsupialisation of hematoma membranes (8, 18). Burr hole craniotomy (BHC) followed by irrigation of the subdural space, with or without drainage, is a widespread treatment for CSH(16, 19, 27). Recurrence rates after the initial drainage procedure range from roughly 5% to 30%, and is a focus of research (19, 27). Thomas Santarius and his colleagues’ randomised controlled trial study showed that patients with CSH treated with burr-hole evacuation and post-operative drainage had a recurrence rate roughly half that of those without drainage (20).

To prevent recurrence of hematoma, Aoki et al. (1) filled the hematoma cavity with oxygen via percutaneous subdural tapping, and found that the recurrence fell to 5%. They concluded that this method eliminated the risk of tension pneumocephalus so long as the inner hematoma membrane was not injured. In comparison with oxygen, Kitakami A et al. (13) used CO₂ gas to fill the hematoma cavity. CO₂ is more rapidly absorbed and facilitates the disappearance of the hematoma cavity and reexpansion of the brain. They found rapid disappearance of the hematoma cavity and almost complete disappearance of the gas within 24 hours of injection of CO₂.

Although corticosteroids have been proven to be clinically effective in the treatment of CSH, the mechanism is still unclear. CSH is currently considered to be a circumscribed chronic self-perpetuating inflammatory disorder that involves the dura mater (23). When CSF or extravasated blood enters into the restricted area of the dural border cell layer (10, 14, 17), it evokes a local aseptic inflammatory (9, 26) and inflammation-induced angiogenic reactions (11, 12, 22, 25). The result is that glucocorticoids may specifically impede the formation of neomembranes and neo-capillaries by their powerful inhibition of inflammatory mediators (23). More basic research is needed to clarify the true role of the corticosteroids in the treatment of chronic subdural hematoma.

CONCLUSION

Our data suggests that local application of MPSS into the hematoma cavity combined with surgery is a safe and effective method in the management of CSH. It may reduce hematoma recurrence. Nevertheless, given the small number of patients and lack of a control group, future carefully designed, prospective, randomized trials are necessary to definitively address these management issues.

ACKNOWLEDGMENTS

The authors would like to thank Qian Wu for his help in editing the article.

REFERENCES


Table 1: Clinical Outcome Measured by the MGS (No. of patients)

<table>
<thead>
<tr>
<th></th>
<th>MGS 0</th>
<th>MGS 1</th>
<th>MGS 2</th>
<th>MGS 3</th>
<th>MGS 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>On admission</td>
<td>13</td>
<td>11</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1 day po.</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>At discharge</td>
<td>26</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
| 12 month po. | 23 | 3 | - | - | - | post-operative, Markwalder Grading Scale: Grade 0: Neurologically normal; Grade 1: Patient alert and oriented; mild symptoms, such as headache; absent or mild symptoms or neurological deficit, such as reflex asymmetry; Grade 2: Drowsy or disorientated, or variable neurological deficit such as hemiparesis; Grade 3: Stuporous, but responding appropriately to noxious stimuli, several focal signs such as hemiplegia; Grade 4: Comatose with absent motor responses to painful stimuli, decerebrate or decorticate posturing.